|Preferred IUPAC name
3D model (JSmol)
CompTox Dashboard (EPA)
|Molar mass||426.71 g/mol|
|Melting point||138 to 140 °C (280 to 284 °F; 411 to 413 K)|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
(what is ?)
|Two molecules of farnesyl pyrophosphate condense with reduction by NADPH to form squalene||squalene synthase|
|Squalene is oxidized to 2,3-oxidosqualene (squalene epoxide)||squalene monooxygenase|
|2,3-Oxidosqualene is converted to a protosterol cation and finally to lanosterol||lanosterol synthase|
|(step 2)||(step 2)|
Lanosterol has been identified as a key component in maintaining eye lens clarity. Pre-clinical research has identified Lanosterol as a possible agent for the reversal and prevention of cataracts. In vivo experiments on dogs showed significant reversal of cataracts within 6 weeks of lanosterol injection. In 2018, Lanosterol was shown to improve lens clarity in subjects with lens clouding due to aging or physical stressors.
Lanosterol is an ingredient in over-the-counter ophthalmic products to prevent cataracts. However, the solubility and bioavailability of lanosterol is not conducive to aqueous formulations. Heliostatix Biotechnology claims to have a method of solubilizing lanosterol for use in aqueous products.